A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.
Solid Tumor
DRUG: ZG005 Powder for Injection|DRUG: Donafenib Tosilate Tablets
Objective Response Rate (ORR), The sum of the proportions of subjects who achieved CR or PR in imaging evaluation as assessed by the investigator based on RECIST1.1 criteria., Up to 2 years|Dose Limiting Toxicity (DLT), A DLT is defined as any of the following â‰¥ Grade 3 adverse events occurring from the first dose to the end of first Cycle (21 days), unless the investigator deems that the AE is clearly related to the disease progress or definitely due to an external cause, Up to 2 years
Duration of response (DOR), Time from the first evaluated CR or PR until PD or death from any cause, Up to 2 years
This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.